Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials

Pfaffendorf, Charlotte; Vonthein, Reinhard; Krockenberger-Ziegler, Katja; Dellas, Kathrin; Schreiber, Andreas; Uhlemann, Dorit; Dinges, Stefan; Würschmidt, Florian; Andreas, P; Weinstrauch, E; Eilf, Kirsten; Rades, Dirk; Höller, Ulrike; Combs, Stephanie E.; Kazmierczak, Renata; Fehlauer, Fabian; Schreck, Ulrike; Zimmer, Jörg; Dunst, Jürgen; Krug, David

doi:10.1016/j.breast.2022.05.008

Cited by 10 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, when a tumor bed boost was needed, a conventionally fractionated boost was used [ 13 ]. A simultaneous Integrated Boost (48 Gy/3.2 Gy per fraction/15 fractions) in this particular clinical situation has also become popular [ 26 , 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Combined Ultrahypofractionated Whole-Breast Irradiation and IORT-Boost: A Safety and Feasibility Analysis

Burgos-Burgos,

Vega,

Macias-Verde

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: The current standard of local treatment for patients with localized breast cancer (BC) includes whole breast irradiation (WBI) after breast-conserving surgery (BCS). Ultrahypofractionated WBI schemes (1-week treatment) were shown not to be inferior to the standard WBI. Tumor bed boost using photon intraoperative radiotherapy (IORT) is safe and feasible in combination with standard WBI. The aim of the present study is to assess, for the first time, the feasibility and safety of combining photon IORT with ultrahypofractionated WBI. Methods: Patients diagnosed with low-risk early BC candidates for BCS were included in this prospective study. IORT was administered at a dose of 20 Gy to the surface’s applicator, and WBI was administered 3–5 weeks after surgery at a total dose of 26 Gy in five consecutive days. Results: From July 2020 to December 2022, seventy-two patients diagnosed with low-risk early BC and treated in our institution were included in this prospective study. All patients completed the proposed treatment, and no severe acute or late grade 3 toxicity was observed 3 and 12 months after WBI, respectively. Conclusions: Our results confirm for the first time that the combination of ultrafractionation WBI and photon-IORT after BCS is a feasible and safe option in patients with early BC.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Ultrahypofractionated Whole-Breast Irradiation and IORT-Boost: A Safety and Feasibility Analysis

Burgos-Burgos,

Vega,

Macias-Verde

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…We used the following hypotheses: Adjuvant breast radiotherapy: No nodal RT, age >75 years: 5 fractions [29] Nodal RT or age <75 years: 15 fractions [30] , [31] (a boost, if indicated, would be a Simultaneous Integrated Boost) [32] , [33] , [34] , [35] Prostate: 20 fractions [36] , [37] Prostatic bed: no change Bone metastasis: 1 fraction [38] , [39] Stereotactic Body Radiation Therapy (SBRT): no change Other treatments: no change …”

Section: General Methodologymentioning

confidence: 99%

“…Adjuvant breast radiotherapy: No nodal RT, age >75 years: 5 fractions [29] Nodal RT or age <75 years: 15 fractions [30] , [31] (a boost, if indicated, would be a Simultaneous Integrated Boost) [32] , [33] , [34] , [35] …”

Section: General Methodologymentioning

confidence: 99%

See 1 more Smart Citation

Methodological guide for assessing the carbon footprint of external beam radiotherapy: A single-center study with quantified mitigation strategies

Ali,

Piffoux

2024

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

“…The phase 3 NRG Radiation Therapy Oncology Group (RTOG) 1005 clinical trial, with a median follow-up of 7.3 years, demonstrated that SIB-mhWBRT is as effective as conventional fractionation with a sequential boost from the point of view of in-breast relapse rates and late adverse effects, for breast cancer patients who do not require regional lymphatic node irradiation. 10 Despite the growing evidence of the safety and efficacy of hypofractionated SIB concept application for adjuvant breast RT, 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 this is still not in widespread clinical use. 1 , 22 In our department, SIB-mhWBRT has been used for the breast since July 2017.…”

Section: Introductionmentioning

confidence: 99%

Single-Institution Prospective Evaluation of Moderately Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost With or Without Lymphatic Drainage Irradiation After Breast-Conserving Surgery

Unterkirhere

Stenger-Weisser

Kaever³

et al. 2023

Advances in Radiation Oncology

View full text Add to dashboard Cite

Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials

Cited by 10 publications

References 34 publications

Combined Ultrahypofractionated Whole-Breast Irradiation and IORT-Boost: A Safety and Feasibility Analysis

Combined Ultrahypofractionated Whole-Breast Irradiation and IORT-Boost: A Safety and Feasibility Analysis

Methodological guide for assessing the carbon footprint of external beam radiotherapy: A single-center study with quantified mitigation strategies

Single-Institution Prospective Evaluation of Moderately Hypofractionated Whole-Breast Radiation Therapy With Simultaneous Integrated Boost With or Without Lymphatic Drainage Irradiation After Breast-Conserving Surgery

Contact Info

Product

Resources

About